News for Entera Bio Ltd. (ENTX)

**media[548587]**

JERUSALEM, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. ( ENTX), (”œEntera” or the ”œCompany”) a leader in the development of orally delivered pept

On November 14, 2024, Knoll Capital Management, LLC (Trades, Portfolio) executed a significant transaction by acquiring an additional 2,000,000 shares of Entera

Entera Bio (ENTX) delivered earnings and revenue surprises of -60% and 5%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[460661]**

Entera Bio shares hold Buy rating on OXM study success

Entera's EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - K

AbbVie (NYSE: ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of Skyrizi (risankizumab) in the EU to treat adults with moderately to severely active ulcerative colitis (UC).

Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

The latest trading day saw Entera Bio Ltd. (ENTX) settling at $1.98, representing a -1% change from its previous close.

In the closing of the recent trading day, Entera Bio Ltd. (ENTX) stood at $2.24, denoting a +0.9% change from the preceding trading day.

The past few years have been a topsy-turvy ride for the biotech sector.

Following the market opening Monday, the Dow traded up 0.02% to 32,783.87 while the NASDAQ rose 0.28% to 13,357.04. However, the S&P fell 0.04% to ...

On Thursday morning, 420 companies hit new 52-week highs. Significant Points: The largest company by market cap to hit a new 52-week high was Visa ...